Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Endo to Acquire HealthTronics to Expand in Urology

May 5 (Bloomberg) -- Endo Pharmaceuticals Holdings Inc., the maker of the painkiller Percocet, said it will acquire HealthTronics Inc., a provider of urologic services and devices, in an all-cash deal for $223 million.

Endo will purchase all outstanding shares of HealthTronics for $4.85 per share, the Chadds Ford, Pennsylvania-based company said in a statement today. The deal is a 34 percent premium on HealthTronics’ $3.62 price at the 4 p.m. New York time close of Nasdaq Stock Market trading. Endo also will assume Austin, Texas-based HealthTronics’ net debt of about $35 million, bringing the value of the deal to about $258 million, the company said in its statement.

The acquisition will expand Endo’s urology offerings to include therapies for prostate cancer and surgical procedures to remove kidney stones. Endo raised its guidance for 2010 revenue to $1.63 billion to $1.68 billion and adjusted earnings per share to $2.06 to $2.14 as a result of the purchase.

“This strategic acquisition immediately elevates Endo from a pharmaceutical company to a diversified partner to physicians and payers in the treatment and diagnosis of urological and pain-related conditions,” Endo Chief Executive Officer Dave Holveck said in the statement.

Endo rose 27 cents, or 1.3 percent, to $21.77 at the close of Nasdaq trading before the deal was announced. The company has gained 34 percent in the past 12 months.

To contact the reporter on this story: Ellen Gibson in New York at egibson9@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.